ANAlexander A. Novikov

Alexander A. Novikov

*This is an algorithmically generated author record based on publicly available information.

Alexander A. Novikov has a total of 260 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of the possibility of using fecal calprotectin for the diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis

    by P. I. Kulakova, G. V. Lukina, E. A. Alexandrova, A. A. Novikov, M. A. Borisova

    The aim . To evaluate the possibility of using fecal calprotectin levels for early diagnosis of inflammatory bowel diseases in patients with AS in real clinical practice. Materials and methods . The analysis included 70 patients with a confirmed diagnosis of AS over the age of 18: 52 men (74.3 %) and 18 women (25.7 %), aged 47.4±8.8 years, with a disease duration of 19.6±7.9 years. All patients underwent blood tests (ESR, CRP, HLAB 27 antigen levels), esophagogastroduodenoscopy and colonoscopy, quantitative analysis of the fecal calprotectin levels using the method of lateral immunochromatography with the BUHLMANN Quantum Blue rapid test (standart range: 100–1800 μg/g). Results . All patients had high disease activity: BASDAI was 5.4±1.4, ASDAS CRP – 3.6±0.8. IBD was diagnosed in 18 cases (25.7 %). In 77 % of patients with AS, the FC level exceeded 100 μg/g, and in 28 % it exceeded 1800 μg/l. The FC level was more than 1000 μg/g in 63 %. In patients with IBD, the FC level was more than 100 μg/g, and the average FC level was higher in patients with IBD (1141.3 μg/g) than without IBD (787 μg/g). No active IBD was detected in all patients with FC levels less than 300 μg/g of feces. FC levels correlated with CRP (r=0.366) and ESR (r=0.366) (pConclusion . Patients with AS and IBD had higher FC levels than patients without IBD. Normal FC levels in patients with AS indicate the absence of intestinal inflammation. There was also a correlation between increased FC levels and the severity of AS. According to the study, measuring fecal calprotectin levels may be useful for detecting intestinal inflammation at an early stage.

  • Inflammatory bowel disease-associated antibodies in ankylosing spondylitis: relationship with clinical and laboratory markers of inflammation

    by E. A. Aleksandrova, A. A. Novikov, P. I. Kulakova, E. N. Koltsova, M. A. Borisova, G. V. Lukina

    Background/Purpose. To study the relationship between levels of antibodies associated with inflammatory bowel diseases (IBD) and inflammatory markers in ankylosing spondylitis (AS). Materials and methods. The sera of 44 healthy donors (HD) and 51 patients with AS were studied: 40 men, 11 women aged 44.0 (34.0–49.0) years with a disease duration of 12.0 (5.0–20.0) years, high disease activity (BASDAI – 5.3; 4.5–6.4; ASDAS ESR – 3.6; 3.0–4.4; ASDAS CRP – 3.7; 2.8–4.5). IBD was diagnosed in 22 % of patients with AS. IgG/IgA antibodies to S. cerevisiae (ASCA), IgG/IgA antibodies to glycoprotein 2 (GP2), IgG antibodies to cathepsin G, elastase, serum calprotectin (sCP), interleukin-6 (IL-6) were determined by ELISA. Results. Patients with AS without IBD and AS with IBD had higher levels of IgA ASCA, IgA aGP2, and elastase antibodies than HD (4.5; 2.6–6.4 U/ml and 4.9; 3.7–7.3 U/ml vs 1.9; 0.6–2.6 U/ml, p=0.0008, p=0.001; 1.2; 0.8–5.5 U/ml and 1.2; 0.9–11.8 U/ml vs 0.7; p=0.007, p=0.02; 8.2; 5.9–9.9 U/ml and 9.1; 8.5–10.5 U/ml vs 5.6; 4.7–8.3 U/ml, p=0.01, p=0.003). The concentration of antibodies to cathepsin G was higher in AS with IBD compared to AS without IBD (0.8; 0.5–1.0 U/ml vs 0.4; 0.3–0.6 U/ml, p=0.02). The levels of IgA ASCA correlated with IL-6 (r=0.3), IgA aGP2 – with sCP (r=0.3), antibodies to elastase – with ESR (r=0.4), antibodies to cathepsin G – with ESR (r=0.4) and BASDAI (r=0.4) (pConclusion. Elevated levels of IgA ASCA, IgA aGP2, and anti-elastase antibodies in AS without IBD are similar to those in AS with IBD. Hyperproduction of IgA ASCA, IgA aGP2, anti-elastase antibodies, and cathepsin G reflects the inflammatory activity of AS.

  • Efficacy and safety of upadacitinib therapy in patients with rheumatoid arthritis in real-world clinical practice: 12-month follow-up results

    by M. A. Borisova, E. N. Koltsova, E. V. Volnukhin, E. S. Zagvozdkina, V. V. Khoninova, A. N. Kovshik, N. A. Savenkova, L. V. Teplova, Е. Н. Александрова, A. A. Novikov, et al.

    Background/Purpose. Upadacitinib (UPA) is an oral Janus kinase inhibitor, which has selectivity of JAK1 over JAK2, JAK3, and tyrosine kinase 2. UPA demonstrated efficacy for the treatment of RA, with acceptable safety profiles. We analyzed efficacy and tolerability of UPA in small Russian cohort of patients with rheumatoid arthritis.Materials and methods. Patients (n=24) with high RA activity (DAS 28 5.1±1.1, SDAI 27,5±11,2, CDAI 24,5±9,7) and an inadequate response of synthetic DMARDs (mainly methotrexate, 71 %) and biologics (mainly TNF-α blockers, 24 %) were included in the study. The majority of patients were middle-aged (46,8±15,4), RF (88 %) and ACPA (84 %) positive, with moderate functional impairment – 1.6 (1.25–2). UPA were administered per os, 15 mg daily. The evaluation of the effectiveness of the therapy was carried out according to the EULAR/ACR 2011 criteria and using SDAI, CDAI.Results. UPA led to a significant (pConclusion. UPA has shown significant improvement clinical status in patients who had an inadequate response to previous therapy. UPA was well tolerated. AE were registered in a small number of patients.

  • Open Access

    Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases

    by G V Lukina, O V Knyazev, E A Belousova, D I Abdulganieva, E N Aleksandrova, I G Bakulin, O I Barysheva, M А Borisova, B А Vykova, A А Godzenko, et al.

    The Russian Cross-disciplinary Consensus on the diagnositic and treatment of spondyloarthritis (SpA) in inflammatory bowel diseases (IBD) was prepared on the initiative of the Loginov Moscow Clinical Scientific Center, using the Delphic system. Its purpose was to consolidate the opinions of experts on the most actual issues of diagnosis and treatment of concomitant immuno-inflammatory diseases (SpA and IBD). An interdisciplinary approach is provided by the participation of leading gastroenterologists and rheumatologists. The working group analyzed domestic and foreign publications on the problem of curation of patients with SpA and IBD. There have been 17 statements and 2 treatment algorithms formulated. Statements 1–3 reflect the fundamental principles of management of patients with SpA and IBD. The principles of early diagnosis of SpA and IBD, including the diagnosis of complications of therapy, are described below. Eleven statements are devoted to current methods of treatment, on the basis of which 2 treatment algorithms have been developed. The statements of the Consensus were submitted to the Expert Council for consideration, edits were made, after which an online vote took place. This paper presents current recommendations for the management, diagnosis and treatment of patients with SpA and IBD.


  • Open Access

    Diagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement)

    by Yu. G. Sandler, E. V. Vinnitskaya, K. L. Raikhelson, K. V. Ivashkin, S. N. Batskikh, E. N. Aleksandrova, D. T. Abdurakhmanov, D. I. Abdulganieva, I. G. Bakulin, A. O. Bueverov, et al.

    Background. In the last decade, the understanding of the pathogenesis of autoimmune hepatitis (AIH) has significantly deepened, based on the results of new clinical studies some diagnostic issues have been revised and immunosuppressive therapy regimens have been optimized.Materials and methods. The latest Russian clinical guidelines for the diagnosis and treatment of AIH were presented in 2013; and in 2017, the first Russian agreement on the diagnosis and treatment of AIH was held. Updating approaches to the management of patients with AIH necessitated next systematization for use in clinical practice. In February 2024, the final session was held to discuss the provisions of the second agreement on the diagnosis and treatment of AIH.Results. This publication presents the main discussion points of the agreement regarding methods and algorithms for detecting autoantibodies, the role of liver biopsy, revised morphological criteria for AIH, optimized immunosuppressive therapy regimens, updated criteria for assessing the response to therapy.Conclusions. The agreement was the result of the work of a group of experts on the diagnosis and treatment of AIH and represents the basis for the creation of updated federal clinical guidelines.


  • Methodological aspects of anti-nuclear antibodies detection: EFLM, EASI, ICAP AND RAMLD recommendations

    by A. A. Novikov, E. N. Aleksandrova, G. V. Lukina, S. P. Kazakov

    This is a review of international and Russian recommendation for the study of anti-nuclear antibodies (ANA) in autoimmune inflammatory rheumatic diseases (AIRD) and autoimmune liver diseases (ALD), including a description of the most important methodological aspects. The main purpose of laboratory diagnostics of AIRD and ALD is to obtain objective information about the presence and immunopathological changes, which is an important tool for early diagnosis, assessment of activity, severity, prognosis of the disease and the effectiveness of therapy. The positive results of ANA determination are the main laboratory markers of AIRD and ALD, being among the diagnostic criteria for diseases. The ‘gold standard’ and primary screening method for determining ANA in serum is the indirect immunofluorescence assay (IFA). Antigen-specific solid phase assays methods are used as confirmatory tests. Standardization of the ANA determination contributes for reducing the intra- and inter-laboratory variability of the results, helps to optimize the interaction between laboratory specialists and clinicians in matters of prescribing and clinical interpretation of ANA tests. Solving the problem of ANA detection standardization is important because of the growing number of laboratories performing these tests and an increased referring for this investigation from rheumatologists and another medical specialist.


  • Cytokines in predicting JAK inhibitors clinical efficacy for COVID-19

    by A. A. Novikov, E. N. Aleksandrova, G. E. Bajmakanova, G. V. Lukina, N. A. Bodunova, V. I. Vechorko, O. V. Averkov, S. N. Shcherbo, M. I. Savina, T. I. Turkina, et al.

    Janus kinases inhibitors (JAKi) have an immunosuppressive effect due to the normalization of levels of proinflammatory cytokines, are used in the treatment of cytokine storm in COVID-19. This fact makes it necessary to search a predictor of an efficacy of this small-molecules.   The aim of the study. To evaluate the possibility of using cytokines in predicting the efficacy of JAKi in COVID-19.   Materials and methods. We examined 86 patients with COVID-19: 50 men and 36 women. The age was 57,0; (50,0–65,0) years. The SARS-CoV-2 presence was confirmed by PCR. The control group consisted of 30 healthy donors matched by sex and age. The criterion for the efficacy of JAKi was recovery, in efficacy – switching to another drug, or death. The serum concentration of IL-1β, –6, –8, –17, TNF-α and GM–CSF by ELISA was estimates using Invitrogen test-systems (USA), according to the manufacturer’s instructions.   Results. In COVID-19 patients who received baricitinib (BTC), compared with healthy individuals, basal (before JAKi starting) IL-6, TNF-α serum concentrations were increased; tofacitinib (TFT) – IL-6, ruxilitinib (RLT) – IL-6 and TNF-α. A decrease of IL-1β and GM–CSF serum concentration was noted before the start of TFT and RLT. Basal concentrations of IL-6 and TNF-α are most statistically strongly associated with the diagnosis COVID-19. After 5 days of treatment with BTC, there was an increase in IL-8 level compared to the basal, a decrease in the GM–CSF concentration and a slight increase IL-6 concentration relative to healthy donors (p < 0.05 in all cases). Basal concentration of IL-17 (more than 13.9 pg/ml) indicated the possibility of successful RLT treatment (area under the ROC-curve = 0.99; AP = 99 %; DS = 80 %; OP+ = 5.0; OP– = 0.2; CI: 0.9–1.0).   Conclusions. Basal serum concentration of cytokines may predict JAKi efficacy in COVID-19 patients.

  • Genetic testing in clinical laboratory diagnostics: Present and future

    by S. N. Shcherbo, D. S. Shcherbo, A. A. Novikov, M. I. Savina, T. I. Turkina

    Authors discuss the current state and prospects for the development of genetic testing in clinical laboratory diagnostics, recent nucleic acids sequencing technologies, their advantages and applications. Although genome-wide association studies (GWAS) have become a standard practice in identifying SNPs to determine disease susceptibility, this approach has limitations. A novel approach is proposed: integrative genome-wide association analysis (iGWAS), which relies on gene expression information to investigate the associations between SNPs and disease phenotype. Numerous studies have shown that iGWAS can significantly facilitate the search for genetic correlations and is superior to a method that relies only on the search for SNPs. Genetic testing will facilitate the molecular-based reclassification of human diseases. Authors describe the technical aspects of nanopore sequencing, the development of an iPhone app to complement miniature sequencing devices, and the world’s first mobile genomic sequence analyzer, iGenomics.

  • АUTOANTIBODIES IN AUTOIMMUNE LIVER DISEASES (REVIEW OF LITERATURE)

    by E.N. Aleksandrova, A.S. Dorofeev, A.A. Novikov, Yu.G. Sandler


  • Open Access

    Diagnostic value of screening methods for the determination of antinuclear antibodies using indirect immunofluorescence on HEp-2 cells and enzyme immunoassay in autoimmune liver diseases

    by Aleksey Sergeevich Dorofeev, E. N. Aleksandrova, A. A. Novikov, K. G. Saliev, Yu. G. Sandler, E. V. Vinnitskaya

    Antinuclear antibodies (ANA) are a heterogeneous group of autoantibodies that react with various components of the cell nucleus and cytoplasm. ANA is the main serological marker for autoimmune liver disease (AILD). The aim of the study was to compare the diagnostic value of two methods of screening for the determination of ANA (indirect immunofluorescence reaction on HEp-2 cells (IIF -HEp-2) and enzyme-linked immunosorbent assay (ELISA) in the sera of AILD patients. The sera of 118 patients with AILD (51 with autoimmune hepatitis - AIH, 19 with primary biliary cholangitis - PBC, 48 with overlapping syndrome - OVERLAP), 30 patients with non-alcoholic fatty liver disease (NAFLD) and 30 healthy donors (HD) were studied. Determination of ANA by the IIF-HEp-2 method was carried out by visual assessment of samples under an AXIOSKOP 40 microscope, by ELISA - on an Alegria automatic analyzer. A weak degree of agreement between the positive and negative results of the ANA screening study using IIF-HEp-2 and ELISA (Cohen’s kappa coefficient æ=0.4) was noted. Screening determination of ANA in patients with AILD by the IIF-HEp-2 method was distinguished by greater diagnostic sensitivity (DS) (68.6%) and a lower frequency of false negative results (31.4%) compared with ELISA (35.6% and 64.4 % respectively, p<0.05). The overall diagnostic specificity (DS) of the ANA study in IIF-HEp-2 was lower than with ELISA (66.7% and 86.7%, respectively, p<0.05). Both screening methods for determining ANA (IIF-HEp-2 and ELISA) were useful for diagnosing AILD (positive likelihood ratio - LR+: 2.1 and 2.6, respectively). In terms of the negative likelihood ratio (LR-), screening for ANA by the IIF-HEp-2 method, in contrast to ELISA, served as a “useful” test to exclude the diagnosis of AILD (0.5 and 0.8, respectively). The determination of ANA using IIF-HEp-2 is the most sensitive and “useful” screening test for the diagnosis of AILD, and ELISA is classified as a less “useful” screening method due to low diagnostic sensitivity and a high false-negative rate.